Skip to main content

Advertisement

Table 2 Comparison between treatments with BBR/P/RR and EZE on plasma lipid concentrations in HCH patients. Six months follow-up

From: Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment

  BBR/P/RR EZE P
Plasma lipids (mmo/L) Baseline On treatment Percent change Baseline On treatment Percent change  
TC 7.63 ± 0.50 5.77 ± 0.49* −24.2 ± 5.2 7.72 ± 0.49 6.25 ± 0.51* −19.0 ± 4.6 < 0.001
LDL-C 5.36 ± 0.48 3.66 ± 0.48* −31.7 ± 7.0 5.36 ± 0.52 4.00 ± 0.52* −25.4 ± 6.4 < 0.001
HDL-C 1.55 ± 0.35 1.54 ± 0.37 −0.64 ± 7.2 1.57 ± 0.34 1.58 ± 0.35 +1.24 ± 6.9 NS
non-HDL-C 6.07 ± 0.54 4.22 ± 0.53* −30.3 ± 6.5 6.15 ± 0.55 4.66 ± 0.58* −24.2 ± 5.9 < 0.001
TG 1.46 (1.22-1.90) 1.12 (0.95-1.41)* −19.5 ± 16.1 1.67 (1.24-2.12) 1.43 (1.08-1.80)* −14.9 ± 11.5 NS
  1. Data are means ± SD or medians (interquartile ranges). *P < 0.001 vs baseline values (Student’s t test for paired data or Wilcoxon test); P: significance of the differences between percent changes induced by BBR/P/RR and by EZE treatments (Student’s t test and Mann–Whitney test, respectively). NS: not significant.